Pharmaceutical

KalVista Pharmaceuticals ( NASDAQ:KALV) has announced it has presented data at he C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. As quoted in the press release: “KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. …

KalVista Pharmaceuticals ( NASDAQ:KALV) has announced it has presented data at he C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary.

As quoted in the press release:

“KVD900 is an oral, novel, potent and selective inhibitor of plasma kallikrein, a validated target in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe KVD900 represents a new therapeutic opportunity to rapidly halt HAE attacks at their earliest sign and we look forward to seeing the Phase 2 data late this year.”

KalVista’s oral presentation and poster showed:

  • KVD900 rapidly reached high levels of drug exposure and was well tolerated without related gastrointestinal adverse events
  • KVD900 successfully interrupts the contact activation system’s positive feedback loop between plasma kallikrein, prekallikrein, and FXII
  • Within 10 minutes an inhibitory effect on plasma kallikrein activity was detected with KVD900 in undiluted plasma and within 20 minutes it was by greater than 95%. KVD900 provided critical high molecular weight kininogen (HK) cleavage protection for at least 10 hours

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21184.95+279.67
TSXV807.38+12.73
DOW34061.06+932.27
S&P 5004300.17+124.69
NASD12964.86+401.10
ASX7316.20-30.80

COMMODITIES

Commodities
Gold1901.08+7.14
Silver23.14+0.14
Copper4.42+0.08
Palladium2280.50+24.50
Platinum1003.00+5.00
Oil108.01+0.20
Heating Oil4.21+0.01
Natural Gas8.54+0.12

DOWNLOAD FREE REPORTS

×